t-cell engagers: targets, challenges and opportunity
Published 2 years ago • 988 plays • Length 19:39Download video MP4
Download video MP3
Similar videos
-
4:16
the challenges with car t-cell therapy for t-all and the progress made to overcome these challenges
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
2:15
challenges with immunotherapy in aml: target antigen selection, t-cell exhaustion and more
-
3:05
updates from the determination trial: rvd vs. autosct in patients with multiple myeloma
-
4:27
how to take a test | cellavision
-
4:50
regulatory t cells
-
2:22
t-cell bispecifics in aml: ongoing challenges and future outlooks
-
1:59
t-cell engagers vs monoclonal antibodies for the treatment of aml: the influence of cd38 expression
-
1:14
the car t-cell strategy vs bispecific antibodies
-
2:18
redirecting t-cell cytotoxicity and proliferation
-
1:10
target antigens for t-cell engager therapies in all and aml
-
0:43
developing an avidcar platform to improve t-cell activity
-
2:41
cell avidity as a predictor of t-cell efficacy
-
2:05
the cost-effectiveness of car t-cell therapy
-
2:11
exploring strategies to mitigate t-cell exhaustion: treatment-free intervals & small molecules
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
2:23
an update on car-t therapy in aml: challenges & emerging strategies
-
1:24
t-cell engaging antibodies: what lessons have we learnt?
-
1:47
identifying positive regulators of t cell functions to improve cellular therapies
-
1:52
single-cell and immune sequencing to predict response and resistance to car-t therapy in r/r mm